QUICK ANSWER · AEO / GEO
FS344 is a follistatin precursor isoform processed to FST315, not the same entity as FST288 or an online recombinant product. Limited human evidence comes from small open-label AAV gene-transfer studies in specific muscle diseases and cannot establish muscle gain, performance or safety in healthy people.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is Follistatin-344?
Follistatin-344 is described pharmacologically as Follistatin precursor isoform and broad TGF-beta-family ligand-binding protein studied through AAV gene transfer. FS344 is a follistatin precursor isoform processed to FST315, not the same entity as FST288 or an online recombinant product. Limited human evidence comes from small open-label AAV gene-transfer studies in specific muscle diseases and cannot establish muscle gain, performance or safety in healthy people.
Does Follistatin-344 have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Follistatin-344 approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.